PRE-TRANSPLANT ASSESSMENT OF NON-HLA ANTIBODY IN INCOMPATIBILITY KIDNEY TRANSPLANT RECIPIENTS

Mary Carmelle Philogene1, Annette Jackson1, Jennifer Metz1, June Jones1, Robert A. Montgomery2, Duska Dragun3, Mary Sue Leffell1, Andrea Zachary1. 1The Johns Hopkins University School of Medicine, Baltimore, MD; 2The Johns Hopkins University School of Medicine, Baltimore, MD; 3Charité - Universitätsmedizin, Berlin, Germany

Abstract:

Aim: To determine the contribution of antibodies to angiotensin II type 1 receptor (AT1R-Ab) and anti-endothelial cell antibody (AECAs) in patients receiving an incompatible kidney transplant, defined as presence of donor specific HLA antibodies (HLA-DSA) or ABO incompatibility between donor and recipient. Methods: AT1R-Ab and AECAs were evaluated prior to transplantation for 54 recipients of an incompatible kidney allograft. The specificity and level of HLA-DSA were evaluated using HLA phenotype (Immucor Gen-Probe, San Diego, CA) and Single Antigen Beads (One Lambda, Canoga Park CA) performed on a Luminex platform. AT1R-Ab and AECAs detection were performed using quantitative ELISA (CellTrend GmbH, Luckenwalde, Germany) and precursor endothelial cell flow cytometric crossmatch (XM-ONE Absorber AB, Stockholm, Sweden). Biopsy diagnosis of rejection was defined according to the Banff 2013 criteria. Results: There were no significant differences in patient or donor demographics, presence (72% versus 69%) or strength of HLA-DSA and AECAs between patients with an AT1R-Ab &gt 17 Units/ml versus AT1R-Ab &lt 17 Units/ml. The incidence of AT1R-Ab &gt 17 Units/ml was greater in patients who had lost a previous graft (96% versus 41%; p = 0.0001). The group with AT1R-Ab &gt 17 Units/ml received an average of 3 (range 0-8) plasmapheresis and IVIG treatments prior to transplantation compared to 2 (range 0-6) treatments in the group with AT1R-Ab &lt 17 Units/ml to remove HLA or ABO antibody prior to transplantation. Three of 25 patients (12%) in the AT1R-Ab &gt 17 Units/ml received eciluzumab compared to 4 of 29 (14%) in the AT1R-Ab &lt 17 Units/ml. Creatinine levels at 5 days post-transplantation were 2.7 and 1.2 respectively for the two groups. Post-transplantation, six kidney transplant recipients with strongly positive AT1R-Ab and no or very low HLA-DSA (&lt 1000 MFI) were treated for biopsy confirmed AMR. Conclusion: Among patients undergoing desensitization for HLA or ABO incompatibility, AT1R-Ab with strength &gt 17 Units/ml, had higher SCr levels at 5 days post-Tx compared to those with AT1R Ab levels &lt 17 Units/ml. The data presented here agree with the reports of others that AT1R-Ab, by itself, can result in AMR. Preemptive detection of AT1R-Ab in patients who are at increased risk of rejection is warranted.

Session: Poster Session – , from 9/29/2015 to 9/29/2015